|
Oct 17
|
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
|
|
Oct 17
|
Theratechnologies Unveils Study Design of PROMISE-US Trial of Ibalizumab
|
|
Oct 17
|
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
|
|
Oct 11
|
Theratechnologies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Oct 11
|
Theratechnologies Inc (THTX) Q3 2024 Earnings Call Highlights: Strong Profitability Amid ...
|
|
Oct 10
|
Theratechnologies Up 12% in U.S. Premarket Trading After Reporting Q3 Swing to Profit
|
|
Oct 10
|
Theratechnologies: Fiscal Q3 Earnings Snapshot
|
|
Oct 10
|
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
|
|
Jun 5
|
Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum
|
|
Jan 2
|
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
|
|
Dec 21
|
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
|
|
Sep 26
|
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
|
|
Sep 25
|
Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
|
|
Sep 25
|
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
|